Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

SELL
$15.95 - $25.18 $28.7 Million - $45.3 Million
-1,800,000 Reduced 67.92%
850,000 $15.9 Million
Q4 2022

Feb 14, 2023

SELL
$13.27 - $17.73 $1.33 Million - $1.77 Million
-100,000 Reduced 3.64%
2,650,000 $42.5 Million
Q3 2022

Nov 14, 2022

BUY
$11.4 - $14.6 $31.4 Million - $40.2 Million
2,750,000 New
2,750,000 $35.8 Million
Q3 2020

Nov 16, 2020

SELL
$40.47 - $45.5 $2.02 Million - $2.28 Million
-50,000 Closed
0 $0
Q1 2020

May 15, 2020

BUY
$23.3 - $45.96 $1.17 Million - $2.3 Million
50,000 New
50,000 $1.74 Million
Q4 2019

Feb 14, 2020

SELL
$34.58 - $48.06 $51.9 Million - $72.1 Million
-1,500,000 Closed
0 $0
Q3 2019

Nov 14, 2019

SELL
$36.98 - $48.45 $7.4 Million - $9.69 Million
-200,000 Reduced 11.76%
1,500,000 $55.5 Million
Q2 2019

Aug 14, 2019

BUY
$35.13 - $55.53 $22.8 Million - $36.1 Million
650,000 Added 61.9%
1,700,000 $76.8 Million
Q1 2019

May 15, 2019

SELL
$42.83 - $59.91 $2.14 Million - $3 Million
-50,000 Reduced 4.55%
1,050,000 $57.1 Million
Q4 2018

Feb 14, 2019

BUY
$37.97 - $60.16 $23 Million - $36.5 Million
607,000 Added 123.12%
1,100,000 $50.9 Million
Q3 2018

Nov 14, 2018

SELL
$56.3 - $67.25 $5.63 Million - $6.73 Million
-100,000 Reduced 16.86%
493,000 $30 Million
Q2 2018

Aug 14, 2018

SELL
$44.9 - $64.95 $9.29 Million - $13.4 Million
-207,000 Reduced 25.87%
593,000 $37.1 Million
Q1 2018

May 15, 2018

SELL
$45.35 - $61.65 $16.5 Million - $22.5 Million
-364,900 Reduced 31.32%
800,000 $37 Million
Q4 2017

Feb 14, 2018

BUY
$41.95 - $60.1 $3.15 Million - $4.51 Million
75,000 Added 6.88%
1,164,900 $55.2 Million
Q3 2017

Nov 14, 2017

BUY
$33.4 - $53.9 $36.4 Million - $58.7 Million
1,089,900
1,089,900 $58.6 Million

Others Institutions Holding FGEN

About FIBROGEN INC


  • Ticker FGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 93,741,200
  • Market Cap $54.4M
  • Description
  • FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...
More about FGEN
Track This Portfolio

Track Adage Capital Partners Gp, L.L.C. Portfolio

Follow Adage Capital Partners Gp, L.L.C. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.